Mizuho Securities Starts Freeline (FRLN) at Buy

March 22, 2021 4:03 PM EDT
Get Alerts FRLN Hot Sheet
Price: $12.25 -1.37%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 20 | New: 68
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Mizuho Securities analyst Difei Yang initiates coverage on Freeline (NASDAQ: FRLN) with a Buy rating and a price target of $27.00.

The analyst comments "Freeline's technology platform uses a proprietary AAV capsid to enable higher transduction efficiency in the liver, which we believe could enable "normalization" of protein deficiencies in hemophilia as well as lysosomal storage disorders. Our proprietary survey suggests strong commercial potential for the company's lead program in Hemophilia B given superior factor activity levels achieved by patients vs. competitors. Confirmation of efficacy/safety is likely to be an important catalyst in 2021/2022. Applicability of Freeline's platform in lysosomal storage disorders could offer additional upside, and we see a good opportunity in Gaucher disease where gene therapy competition is currently limited."

For an analyst ratings summary and ratings history on Freeline click here. For more ratings news on Freeline click here.

Shares of Freeline closed at $13.60 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage